+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

European Dry Powdered Inhaler Market 2019-2025

  • ID: 4987997
  • Report
  • January 2020
  • Region: Europe
  • Orion Market Research Private Limited
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 3M Co.
  • Adherium Ltd.
  • Bespak
  • GlaxoSmithKline PLC
  • Novartis AG
  • Pulmatrix Inc.
  • MORE
European Dry Powdered Inhaler Market Size, Share & Trends Analysis Report by Type (Preventive Inhaler, Reliever Inhaler, and Long-Acting Bronchodilators Inhaler), by Application (Asthma and Chronic Obstructive Pulmonary Disease (COPD)), by End-User (Homecare and Hospitals and Clinics) and Forecast 2019-2025.

The European Dry Powdered Inhaler market was valued at around $3.7 billion in 2018 and is anticipated to grow at a substantial rate of 2.1% during the forecast period. Major countries that will contribute to the dry powdered inhaler market within the region includes UK, Germany, France, Italy, and Spain. A significant number of companies, research, patient base has been observed in the market due to which a significant growth can be observed in the market. According to the International Monetary Fund (IMF), Europe is home to around 740 million people and the GDP of the European Union is $19.7 trillion in 2017. As per Organization for Economic Co-operation and Development (OECD), the self-reported asthma rate and COPD rate by European Union countries were 6.1% and 4.0% respectively and it has been found out that the rate of prevalence of diseases are higher in women as compared to men. This is expected to drive the regional business growth of the dry powdered inhaler market.

The European dry powdered inhaler market is segmented based on type, application, and end-user. Based on the type, preventive, reliever, and long-acting bronchodilators inhaler are analyzed. The preventive dry powdered inhaler segment led the global dry powdered inhaler market in 2018. Preventive inhalers are most widely used in the treatment of asthma in children and adults. These inhalers do not entail side effects for long-term use, and exceptionally decreases the possibility of an asthma exacerbation. The preventive inhalers further reduce the airways swelling and hence, are recommended for regular use by the physician. Some of the preventive inhalers available in the market include Budesonide and Fluticasone. Moreover, based on the application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing dry powdered inhalers to cater to a wide range of customers within the region and across the globe. The major players of the European dry powdered inhaler market include Boehringer Ingelheim International GmbH, AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, Teva Pharmaceuticals Industries Ltd., Koninklijke Philips N.V., and Bespak. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.

Research Methodology

The market study of the European dry powdered inhaler market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors.

Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for dry powdered inhaler manufacturers, inhaler manufacturing companies, contract research organizations (CROs), healthcare sector, market research firms, and government organizations, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation

1. European Dry Powdered Inhaler Market Research and Analysis by Type
2. European Dry Powdered Inhaler Market Research and Analysis by Application
3. European Dry Powdered Inhaler Market Research and Analysis by End-User

The Report Covers
  • Comprehensive research methodology of the European dry powdered inhaler market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the European dry powdered inhaler market.
  • Insights about market determinants which are stimulating the European dry powdered inhaler market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 3M Co.
  • Adherium Ltd.
  • Bespak
  • GlaxoSmithKline PLC
  • Novartis AG
  • Pulmatrix Inc.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. European Dry Powdered Inhaler Market by Type
5.1.1. Preventive Inhaler
5.1.2. Reliever Inhaler
5.1.3. Long Acting Bronchodilators Dry Powdered Inhaler
5.2. European Dry Powdered Inhaler Market by Application
5.2.1. Asthma
5.2.2. Chronic Obstructive Pulmonary Disease (COPD)
5.3. European Dry Powdered Inhaler Market by End-User
5.3.1. Homecare
5.3.2. Hospitals and Clinics

6. Regional Analysis
6.1. UK
6.2. Germany
6.3. France
6.4. Italy
6.5. Spain
6.6. RoE

7. Company Profiles
7.1. 3M Co.
7.2. Acorda Therapeutics, Inc.
7.3. Adamis Pharmaceuticals Corp.
7.4. Adherium Ltd.
7.5. AstraZeneca PLC
7.6. Bespak
7.7. Boehringer Ingelheim International GmbH
7.8. Chiesi Farmaceutici S.P.A.
7.9. GF Health
7.10. GlaxoSmithKline PLC
7.11. H&T Presspart Manufacturing Ltd.
7.12. Koninklijke Philips N.V.
7.13. Novartis AG
7.14. Omron Healthcare Inc.
7.15. ResMed Corp.
7.16. Pulmatrix Inc.
7.17. Savara, Inc.
7.18. Teicos Pharma Ltd.
7.19. Teva Pharmaceuticals Industries Ltd.
7.20. Vitalograph Ltd.
Note: Product cover images may vary from those shown
3 of 3
  • 3M Co.
  • Acorda Therapeutics, Inc.
  • Adamis Pharmaceuticals Corp.
  • Adherium Ltd.
  • AstraZeneca PLC
  • Bespak
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici S.P.A.
  • GF Health
  • GlaxoSmithKline PLC
  • H&T Presspart Manufacturing Ltd.
  • Koninklijke Philips N.V.
  • Novartis AG
  • Omron Healthcare Inc.
  • ResMed Corp.
  • Pulmatrix Inc.
  • Savara, Inc.
  • Teicos Pharma Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Vitalograph Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll